Cargando…
Thin film hydration versus modified spraying technique to fabricate intranasal spanlastic nanovesicles for rasagiline mesylate brain delivery: Characterization, statistical optimization, and in vivo pharmacokinetic evaluation
Rasagiline mesylate (RM) is a monoamine oxidase inhibitor that is commonly used to alleviate the symptoms of Parkinson’s disease. However, it suffers from low oral bioavailability due to its extensive hepatic metabolism in addition to its hydrophilic nature which limits its ability to pass through t...
Autores principales: | Ali, Mohamed Mahmoud, Shoukri, Raguia Aly, Yousry, Carol |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981512/ https://www.ncbi.nlm.nih.gov/pubmed/36585559 http://dx.doi.org/10.1007/s13346-022-01285-5 |
Ejemplares similares
-
Effect of the moist-heat sterilization on fabricated nanoscale solid lipid particles containing rasagiline mesylate
por: Viveksarathi, K., et al.
Publicado: (2015) -
Investigating the Targeting Power to Brain Tissues of Intranasal Rasagiline Mesylate-Loaded Transferosomal In Situ Gel for Efficient Treatment of Parkinson’s Disease
por: ElShagea, Hala N., et al.
Publicado: (2023) -
Zein/Phospholipid Composite Nanoparticles for Successful Delivery of Gallic Acid into aHSCs: Influence of Size, Surface Charge, and Vitamin A Coupling
por: Radwan, Shaimaa Ali Ali, et al.
Publicado: (2020) -
Formulation-by-Design of Efinaconazole Spanlastic Nanovesicles for Transungual Delivery Using Statistical Risk Management and Multivariate Analytical Techniques
por: Almuqbil, Rashed M., et al.
Publicado: (2022) -
The neuroprotective agent Rasagiline mesylate attenuates cardiac remodeling after experimental myocardial infarction
por: Varela, Aimilia, et al.
Publicado: (2017)